Adjuvant Breast, Breast
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Eligible for screening study DCP 001
S1418 Step 1 Registration re-activated on February 5, 2021 at 12:00 pm Pacific Time.
Site Delegation of Tasks Log required prior to registration of any patients.
Effective June 23, 2020, the BAHO substudy for SWOG study S1418/BR006, is permanently closed to accrual.